313 related articles for article (PubMed ID: 21967026)
1. Effects of lisinopril, irbesartan, and amlodipine on the thrombogenic variables in the early and late stages of the treatment in hypertensive patients.
Tiryaki O; Usalan C; Buyukhatipoglu H; Sayiner ZA; Kilisli H
Clin Exp Hypertens; 2012; 34(2):145-52. PubMed ID: 21967026
[TBL] [Abstract][Full Text] [Related]
2. Antihypertensive drugs and fibrinolytic function.
Fogari R; Zoppi A
Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
[TBL] [Abstract][Full Text] [Related]
3. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
5. Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.
Fogari R; Preti P; Lazzari P; Corradi L; Zoppi A; Fogari E; Mugellini A
Eur J Clin Pharmacol; 2003 Aug; 59(4):271-5. PubMed ID: 12830340
[TBL] [Abstract][Full Text] [Related]
6. Effects of candesartan and lisinopril on the fibrinolytic system in hypertensive patients.
Hirschl MM; Bur A; Woisetschlaeger C; Derhaschnig U; Laggner AN
J Clin Hypertens (Greenwich); 2007 Jun; 9(6):430-5. PubMed ID: 17541328
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological and clinical properties of AIMIX® combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate].
Mori M; Takahashi S
Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):39-46. PubMed ID: 23842227
[No Abstract] [Full Text] [Related]
8. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
Frampton JE; Scott LJ
Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840
[TBL] [Abstract][Full Text] [Related]
9. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of irbesartan on plasma aldosterone concentration and left atrial volume in hypertensive patients.
Masaki M; Komamura K; Goda A; Hirotani S; Otsuka M; Nakabo A; Fukui M; Fujiwara S; Sugahara M; Lee-Kawabata M; Tsujino T; Koshiba M; Masuyama T
J Cardiol; 2014 Mar; 63(3):205-10. PubMed ID: 24060523
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
da Silva PM
Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210
[TBL] [Abstract][Full Text] [Related]
12. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
[TBL] [Abstract][Full Text] [Related]
13. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Ogihara T; Fujimoto A; Nakao K; Saruta T;
Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
[TBL] [Abstract][Full Text] [Related]
14. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
Bobrie G;
Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibition and fibrinolytic balance.
Matsumoto T; Horie M
Hypertens Res; 2011 Apr; 34(4):448-9. PubMed ID: 21326308
[No Abstract] [Full Text] [Related]
16. Olmesartan/amlodipine: blood pressure lowering and beyond in special populations.
Erdine S
Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):31-44. PubMed ID: 22222315
[TBL] [Abstract][Full Text] [Related]
17. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
Bobrie G;
Clin Ther; 2012 Aug; 34(8):1705-19. PubMed ID: 22853848
[TBL] [Abstract][Full Text] [Related]
18. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
Hasler C; Nussberger J; Maillard M; Forclaz A; Brunner HR; Burnier M
Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
[TBL] [Abstract][Full Text] [Related]
19. Irbesartan improves arterial compliance more than lisinopril.
Ali K; Rajkumar C; Fantin F; Schiff R; Bulpitt CJ
Vasc Health Risk Manag; 2009; 5(4):587-92. PubMed ID: 19649309
[TBL] [Abstract][Full Text] [Related]
20. Discordant responses to two classes of drugs acting on the renin-angiotensin system.
Sever PS; Chang CL
J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1):25-30. PubMed ID: 11881062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]